Isopropyl alcohol
RTECS #
NT8050000
CAS #
Updated
December 2018
Molecular Weight
60.11
Molecular Formula
C3H8O
Synonyms
1-Methylethanol
1-Methylethyl alcohol
2-Hydroxypropane
2-Propanol
2-Propyl alcohol
Alcojel
Alcool isopropilico (Italian)
Alcool isopropylique (French)
Alcosolve
Avantin
Avantine
Combi-schutz
Dimethylcarbinol
Hartosol
Imsol A
i-Propanol (German)
i-Propylalkohol (German)
IPS 1 (alcohol)
Isohol
Isopropanol
Isopropyl alcohol (ACGIH:OSHA)
Iso-propylalkohol (German)
Lutosol
n-Propan-2-ol
Petrohol
PRO
sec-Propyl alcohol
Spectrar
Sterisol hand disinfectant
Takineocol
Virahol
1-Methylethyl alcohol
2-Hydroxypropane
2-Propanol
2-Propyl alcohol
Alcojel
Alcool isopropilico (Italian)
Alcool isopropylique (French)
Alcosolve
Avantin
Avantine
Combi-schutz
Dimethylcarbinol
Hartosol
Imsol A
i-Propanol (German)
i-Propylalkohol (German)
IPS 1 (alcohol)
Isohol
Isopropanol
Isopropyl alcohol (ACGIH:OSHA)
Iso-propylalkohol (German)
Lutosol
n-Propan-2-ol
Petrohol
PRO
sec-Propyl alcohol
Spectrar
Sterisol hand disinfectant
Takineocol
Virahol
Skin and Eye Irritation and References
| Route/Organism | Dose | Effect | Reference |
|---|---|---|---|
| eye /rabbit | 100 mg | severe | AJOPAA 29,1363,1946 |
| eye /rabbit | 10 mg | moderate | TXAPA9 55,501,1980 |
| eye /rabbit | 100 mg/24H | moderate | 85JCAE -,191,1986 |
| skin /rabbit | 500 mg | mild | NTIS** AD-A106-944 |
Mutation Data and Reference
| System Test | Route/Organism/Tissue | Dose | Reference |
|---|---|---|---|
| Cytogenetic Analysis | inhalation/rat | 1030 µg/m3/16W- intermittent | GTPZAB 25(7),33,1981 |
| sex chromosome loss and nondisjunction | inhalation/Drosophila melanogaster | 25 pph | MUREAV 726,215,2011 |
| specific locus test | inhalation/Drosophila melanogaster | 50 pph | MUREAV 726,215,2011 |
Reproductive Effects Data and References
| Route/Organism | Dose | Effect | Reference |
|---|---|---|---|
| inhalation/rat | 3500 ppm/7H (1-19D pregnant) | Reproductive: Effects on embryo or fetus: Fetotoxicity (except death, e.g., stunted fetus) | FCTOD7 26,247,1988 |
| inhalation/rat | 10000 ppm/7H (1-19D pregnant) | Reproductive: Effects on fertility: Pre- implantation mortality (e.g., reduction in number of implants per female; total number of implants per corpora lutea) Reproductive: Effects on fertility: Post- implantation mortality (e.g., dead and/or resorbed implants per total number of implants) Reproductive: Effects on embryo or fetus: Fetal death | FCTOD7 26,247,1988 |
| inhalation/rat | 7000 ppm/7H (1-19D pregnant) | Reproductive: Specific developmental abnormalities: Musculoskeletal system | FCTOD7 26,247,1988 |
| oral/rabbit | 6240 mg/kg (6-18D pregnant) | Reproductive: Other effects on female | FAATDF 22,139,1994 |
| oral/rat | 3276 mg/kg (182D prior to copulation) | Reproductive: Other developmental abnormalities Reproductive: Effects on newborn: Viability index (e.g., # alive at day 4 per # born alive) Reproductive: Effects on newborn: Growth statistics (e.g., reduced weight gain) | VCVGK* -,98,1994 |
| oral/rat | 2278 mg/kg (6-16D pregnant) | Reproductive: Other effects on female Reproductive: Effects on newborn: Viability index (e.g., # alive at day 4 per # born alive) | BDERB* 83,459,2008 |
| oral/rat | 11340 mg/kg (45D prior to copulation) | Reproductive: Maternal effects: Menstrual cycle changes or disorders | GISAAA 43(1),8,1978 |
| oral/rat | 5040 mg/kg (1-20D pregnant) | Reproductive: Effects on fertility: Litter size (e.g., # fetuses per litter; measured before birth) | GISAAA 43(1),8,1978 |
| oral/rat | 8 gm/kg (6-15D pregnant) | Reproductive: Effects on embryo or fetus: Fetotoxicity (except death, e.g., stunted fetus) | RTOPDW 23,183,1996 |
| oral/rat | 32400 µg/kg (26W prior to copulation) | Reproductive: Effects on embryo or fetus: Fetal death | GISAAA 43(1),8,1978 |
| oral/rat | 3500 gm/kg (multigeneration) | Reproductive: Effects on fertility: Mating performance (e.g., # sperm positive females per # females mated; # copulations per # estrus cycles) | TOXID9 13,75,1993 |
Acute Toxicity Data and References
| Route/Organism | Dose | Effect | Reference |
|---|---|---|---|
| In Vitro/Chicken, neurons | Inhibitor Concentration (50 percent kill): 394389 µmol/L/21H | In Vitro Toxicity Studies: Cell viability (mitochondrial reductase assays): MTT, XTT, MTS, WSTs assays etc. | TIVIEQ 7,653,1993 |
| In Vitro/Chicken, neurons | Inhibitor Concentration (10 percent kill): 44999 µmol/L/21H | In Vitro Toxicity Studies: Cell viability (mitochondrial reductase assays): MTT, XTT, MTS, WSTs assays etc. | TIVIEQ 7,653,1993 |
| In Vitro/Chicken, neurons | Inhibitor Concentration (50 percent kill): 344989 µmol/L/20H | In Vitro Toxicity Studies: Cell viability (lysosomal damage): neutral red assay etc. | TIVIEQ 7,653,1993 |
| In Vitro/Chicken, neurons | Inhibitor Concentration (10 percent kill): 68128 µmol/L/20H | In Vitro Toxicity Studies: Cell viability (lysosomal damage): neutral red assay etc. | TIVIEQ 7,653,1993 |
| In Vitro/Hamster, lung fibroblast | Inhibitor Concentration (50 percent kill): 84 mmol/L/60H | In Vitro Toxicity Studies: Cell counting | TIVIEQ 7,511,1993 |
| In Vitro/Hamster, lung fibroblast | Inhibitor Concentration (10 percent kill): 11.5 mmol/L/60H | In Vitro Toxicity Studies: Cell counting | TIVIEQ 7,511,1993 |
| In Vitro/Hamster, lung fibroblast | Inhibitor Concentration Low: >104 mmol/L/24H | In Vitro Toxicity Studies: Cell viability (lysosomal damage): neutral red assay etc. | TIVIEQ 1,3,1987 |
| In Vitro/Human, HeLa cell | Inhibitor Concentration (50 percent kill): 700.5 mmol/L/60H | In Vitro Toxicity Studies: Cell counting | TIVIEQ 7,511,1993 |
| In Vitro/Human, HeLa cell | Inhibitor Concentration (10 percent kill): 6.5 mmol/L/60H | In Vitro Toxicity Studies: Cell counting | TIVIEQ 7,511,1993 |
| In Vitro/Human, kidney tumor | Inhibitor Concentration (50 percent kill): 45500 mg/L | In Vitro Toxicity Studies: Cell viability (dye exclusion): trypan blue assay etc. | TIVIEQ 27,1347,2013 |
| In Vitro/Human, leukemia cells | Inhibitor Concentration (5 percent kill): >25000 mg/L/30M | In Vitro Toxicity Studies: Cell counting | TIVIEQ 27,857,2013 |
| In Vitro/Human, liver | Inhibitor Concentration (50 percent kill): 49 µmol/L/24H | In Vitro Toxicity Studies: Cell viability (mitochondrial reductase assays): MTT, XTT, MTS, WSTs assays etc. | TIVIEQ 6,47,1992 |
| In Vitro/Human, liver tumor | Inhibitor Concentration Low: >91 mmol/L/24H | In Vitro Toxicity Studies: Cell viability (lysosomal damage): neutral red assay etc. | TIVIEQ 1,3,1987 |
| In Vitro/Human, liver tumor | Inhibitor Concentration (50 percent kill): 256 mmol/L/24H | In Vitro Toxicity Studies: Cell protein synthesis | TIVIEQ 3,189,1989 |
| In Vitro/Human, liver tumor | Inhibitor Concentration (50 percent kill): 4830 mg/L/24H | In Vitro Toxicity Studies: Cell viability (mitochondrial reductase assays): MTT, XTT, MTS, WSTs assays etc. | TIVIEQ 27,1347,2013 |
| In Vitro/Human, liver tumor | Inhibitor Concentration (50 percent kill): 39700 mg/L | In Vitro Toxicity Studies: Cell viability (dye exclusion): trypan blue assay etc. | TIVIEQ 27,1347,2013 |
| In Vitro/Human, lymphocyte | Inhibitor Concentration (30 percent kill): >200 mg/L/45H | In Vitro Toxicity Studies: Cell viability (dye exclusion): trypan blue assay etc. | TIVIEQ 29,901,2015 |
| In Vitro/Human, lymphocyte | Inhibitor Concentration (50 percent kill): >200 mg/L/45H | In Vitro Toxicity Studies: Other assays | TIVIEQ 29,901,2015 |
| In Vitro/Human, monocyte | Inhibitor Concentration (20 percent kill): >10000 µmol/L/24H | In Vitro Toxicity Studies: Cell viability (mitochondrial reductase assays): MTT, XTT, MTS, WSTs assays etc. | TOLED5 199,51,2010 |
| In Vitro/Human, monocyte | Inhibitor Concentration (20 percent kill): 10 mmol/L/2H | In Vitro Toxicity Studies: Other assays | TOLED5 199,51,2010 |
| In Vitro/Human, neuroblastoma | Inhibitor Concentration (20 percent kill): 12 mmol/L/30M | In Vitro Toxicity Studies: Other assays | TXAPA9 245,191,2010 |
| In Vitro/Human, neuroblastoma | Inhibitor Concentration (50 percent kill): 2480 mg/L | In Vitro Toxicity Studies: Cell viability (dye exclusion): trypan blue assay etc. | TIVIEQ 27,1347,2013 |
| In Vitro/Human, skin | Inhibitor Concentration (50 percent kill): >2000 µmol/L/48H | In Vitro Toxicity Studies: Cell viability (mitochondrial reductase assays): MTT, XTT, MTS, WSTs assays etc. | TIVIEQ 29,688,2015 |
| In Vitro/Human, skin | Inhibitor Concentration (50 percent kill): >2000 µmol/L/48H | In Vitro Toxicity Studies: Cell metabolic activity: Alamar Blue assay etc. | TIVIEQ 29,688,2015 |
| In Vitro/Human, skin | Inhibitor Concentration (30 percent kill): >2000 µmol/L/48H | In Vitro Toxicity Studies: Cell viability (mitochondrial reductase assays): MTT, XTT, MTS, WSTs assays etc. | TIVIEQ 29,688,2015 |
| In Vitro/Human, skin | Inhibitor Concentration (30 percent kill): >2000 µmol/L/48H | In Vitro Toxicity Studies: Cell metabolic activity: Alamar Blue assay etc. | TIVIEQ 29,688,2015 |
| In Vitro/Human, skin | Inhibitor Concentration (20 percent kill): 15.0 mg/L/21H | In Vitro Toxicity Studies: Cell viability (mitochondrial reductase assays): MTT, XTT, MTS, WSTs assays etc. | TIVIEQ 27,314,2013 |
| In Vitro/Human, skin | Inhibitor Concentration (50 percent kill): 4660 mg/L/48H | In Vitro Toxicity Studies: Cell viability (lysosomal damage): neutral red assay etc. | TIVIEQ 27,1347,2013 |
| In Vitro/Human, skin | Inhibitor Concentration (50 percent kill): 109000 mg/L/1M | In Vitro Toxicity Studies: Cell viability (lysosomal damage): neutral red assay etc. | TIVIEQ 6,367,1992 |
| In Vitro/jda | Inhibitor Concentration (50 percent kill): 401672 mg/L/1H | In Vitro Toxicity Studies: Cell viability (mitochondrial reductase assays): MTT, XTT, MTS, WSTs assays etc. | TOLED5 212,198,2012 |
| In Vitro/Mouse, fibroblast | Inhibitor Concentration (50 percent kill): 48 µmol/L/24H | In Vitro Toxicity Studies: Cell viability (mitochondrial reductase assays): MTT, XTT, MTS, WSTs assays etc. | TIVIEQ 6,47,1992 |
| In Vitro/Mouse, fibroblast | Inhibitor Concentration (50 percent kill): 3950 mg/L/48H | In Vitro Toxicity Studies: Cell viability (lysosomal damage): neutral red assay etc. | TIVIEQ 27,1347,2013 |
| In Vitro/Mouse, fibroblast | Inhibitor Concentration Low: >104 mmol/L/24H | In Vitro Toxicity Studies: Cell viability (lysosomal damage): neutral red assay etc. | TIVIEQ 1,3,1987 |
| In Vitro/Mouse, fibroblast | Inhibitor Concentration (50 percent kill): 414 mmol/L/48H | In Vitro Toxicity Studies: Cell viability (lysosomal damage): neutral red assay etc. | TIVIEQ 5,449,1991 |
| In Vitro/Mouse, fibroblast | Inhibitor Concentration (50 percent kill): 184 mmol/L/72H | In Vitro Toxicity Studies: Cell viability (lysosomal damage): neutral red assay etc. | TIVIEQ 5,449,1991 |
| In Vitro/Mouse, fibroblast | Inhibitor Concentration (50 percent kill): 523 mmol/L/48H | In Vitro Toxicity Studies: Cell protein synthesis | TIVIEQ 5,449,1991 |
| In Vitro/Mouse, fibroblast | Inhibitor Concentration (50 percent kill): 300 mmol/L/72H | In Vitro Toxicity Studies: Cell protein synthesis | TIVIEQ 5,449,1991 |
| In Vitro/Mouse, fibroblast | Inhibitor Concentration (50 percent kill): 400 mmol/L/48H | In Vitro Toxicity Studies: Cell viability (mitochondrial reductase assays): MTT, XTT, MTS, WSTs assays etc. | TIVIEQ 5,449,1991 |
| In Vitro/Mouse, fibroblast | Inhibitor Concentration (50 percent kill): 326 mmol/L/72H | In Vitro Toxicity Studies: Cell viability (mitochondrial reductase assays): MTT, XTT, MTS, WSTs assays etc. | TIVIEQ 5,449,1991 |
| In Vitro/Mouse, liver | Inhibitor Concentration (50 percent kill): 520 mmol/L/2H | Biochemical: Enzyme inhibition, induction, or change in blood or tissue levels: Dehydrogenases Biochemical: Enzyme inhibition, induction, or change in blood or tissue levels: Transaminases | TIVIEQ 4,783,1990 |
| In Vitro/Mouse, macrophage | Inhibitor Concentration Low: >104 mmol/L/24H | In Vitro Toxicity Studies: Cell viability (lysosomal damage): neutral red assay etc. | TIVIEQ 1,3,1987 |
| In Vitro/mra | Inhibitor Concentration (25 percent kill): 5000 mg/L/24H | In Vitro Toxicity Studies: Cell viability (mitochondrial reductase assays): MTT, XTT, MTS, WSTs assays etc. | TOLED5 216,65,2013 |
| In Vitro/mra | Inhibitor Concentration Low: 2500 mg/L/24H | Biochemical: Metabolism (intermediary): Effect on inflammation or mediation of inflammation | TOLED5 216,65,2013 |
| In Vitro/Non-mammalian species, fibroblast | Inhibitor Concentration (50 percent kill): 568 mmol/L/24H | In Vitro Toxicity Studies: Cell counting | TIVIEQ 7,537,1993 |
| In Vitro/paa | Inhibitor Concentration Low: 28.6 mmol/L/44H | In Vitro Toxicity Studies: Other assays | TIVIEQ 27,1416,2013 |
| In Vitro/Rat, liver | Inhibitor Concentration (50 percent kill): 41 µmol/L/24H | In Vitro Toxicity Studies: Cell viability (mitochondrial reductase assays): MTT, XTT, MTS, WSTs assays etc. | TIVIEQ 6,47,1992 |
| In Vitro/Rat, liver | Inhibitor Concentration (50 percent kill): 14600 mg/L/24H | In Vitro Toxicity Studies: Cell viability (mitochondrial reductase assays): MTT, XTT, MTS, WSTs assays etc. | TIVIEQ 27,1347,2013 |
| In Vitro/Rat, lung | Inhibitor Concentration (50 percent kill): 10.9 gm/L/24H | In Vitro Toxicity Studies: Cell membrane integrity (prelabeled cells): release of radioactive isotopes ([51Cr], [3H]-thymidine, [3H]-proline, [35S]- or [75Se]-methionine, 5-[125I]-2-deoxy-uridine) or fluorescent dyes (bis-carboxyethyl-carboxyfluorescein (BCECF) or calcein-AM) | TIVIEQ 7,111,1993 |
| In Vitro/Rat, lung | Inhibitor Concentration (50 percent kill): 8.1 gm/L/24H | In Vitro Toxicity Studies: Cell viability (mitochondrial reductase assays): MTT, XTT, MTS, WSTs assays etc. | TIVIEQ 7,111,1993 |
| In Vitro/Rat, lung | Inhibitor Concentration (10 percent kill): 6.03 gm/L/24H | In Vitro Toxicity Studies: Cell membrane integrity (prelabeled cells): release of radioactive isotopes ([51Cr], [3H]-thymidine, [3H]-proline, [35S]- or [75Se]-methionine, 5-[125I]-2-deoxy-uridine) or fluorescent dyes (bis-carboxyethyl-carboxyfluorescein (BCECF) or calcein-AM) | TIVIEQ 7,111,1993 |
| In Vitro/Rat, lung | Inhibitor Concentration (75 percent kill): 15.9 gm/L/24H | In Vitro Toxicity Studies: Cell membrane integrity (prelabeled cells): release of radioactive isotopes ([51Cr], [3H]-thymidine, [3H]-proline, [35S]- or [75Se]-methionine, 5-[125I]-2-deoxy-uridine) or fluorescent dyes (bis-carboxyethyl-carboxyfluorescein (BCECF) or calcein-AM) | TIVIEQ 7,111,1993 |
| In Vitro/Rat, lung | Inhibitor Concentration (10 percent kill): 5.6 gm/L/24H | In Vitro Toxicity Studies: Cell viability (mitochondrial reductase assays): MTT, XTT, MTS, WSTs assays etc. | TIVIEQ 7,111,1993 |
| In Vitro/Rat, lung | Inhibitor Concentration (75 percent kill): 10.2 gm/L/24H | In Vitro Toxicity Studies: Cell viability (mitochondrial reductase assays): MTT, XTT, MTS, WSTs assays etc. | TIVIEQ 7,111,1993 |
| inhalation/guinea pig | lowest published toxic concentration: 980 mg/m3/24H | Ear: Tumors Behavioral: General anesthetic Lung, Thorax, or Respiration: Other changes | VCVGK* -,97,1984 |
| inhalation/human | lowest published toxic concentration: 35 ppm/4H | Cardiac: Pulse rate decreased with fall in BP Lung, Thorax, or Respiration: Other changes | NRTXDN 24,179,2003 |
| inhalation/human | lowest published toxic concentration: 150 ppm/2H | Biochemical: Enzyme inhibition, induction, or change in blood or tissue levels: Other enzymes | TOXID9 60,428,2001 |
| inhalation/mouse | lowest published toxic concentration: 3000 ppm/6M | Lung, Thorax, or Respiration: Respiratory depression | TOLED5 9,137,1981 |
| inhalation/mouse | lethal concentration (50 percent kill): 53000 mg/m3 | Behavioral: General anesthetic Lung, Thorax, or Respiration: Other changes | VCVGK* -,97,1984 |
| inhalation/mouse | Lowest published lethal concentration: 12800 ppm/3H | IAEC** 17JUN1974 | |
| inhalation/rat | lethal concentration (50 percent kill): 16000 ppm/8H | NPIRI* 1,100,1974 | |
| inhalation/rat | lethal concentration (50 percent kill): 72600 mg/m3 | Behavioral: General anesthetic Lung, Thorax, or Respiration: Other changes | VCVGK* -,97,1984 |
| intraperitoneal/guinea pig | lethal dose (50 percent kill): 2560 mg/kg | EVHPAZ 61,321,1985 | |
| intraperitoneal/hamster | lethal dose (50 percent kill): 3444 mg/kg | EVHPAZ 61,321,1985 | |
| intraperitoneal/mouse | lethal dose (50 percent kill): 4477 mg/kg | EVHPAZ 61,321,1985 | |
| intraperitoneal/rabbit | lethal dose (50 percent kill): 667 mg/kg | EVHPAZ 61,321,1985 | |
| intraperitoneal/rat | lowest published toxic dose: 800 mg/kg | Behavioral: Ataxia | VCVGK* -,97,1984 |
| intraperitoneal/rat | lethal dose (50 percent kill): 2735 mg/kg | EVHPAZ 61,321,1985 | |
| intravenous/cat | lowest published lethal dose: 1963 mg/kg | HBTXAC 1,172,1955 | |
| intravenous/Dog | lowest published lethal dose: 1024 mg/kg | JLCMAK 29,561,1944 | |
| intravenous/mouse | lethal dose (50 percent kill): 1509 mg/kg | ENTOX* ,706,2005 | |
| intravenous/rabbit | lethal dose (50 percent kill): 1184 mg/kg | EVHPAZ 61,321,1985 | |
| intravenous/rat | lethal dose (50 percent kill): 1088 mg/kg | EVHPAZ 61,321,1985 | |
| oral/cat | lowest published lethal dose: 6 mL/kg | AIPTAK 26,285,1921 | |
| oral/Dog | lowest published lethal dose: 1537 mg/kg | Gastrointestinal: Nausea or vomiting | JLCMAK 29,561,1944 |
| oral/human | lowest published lethal dose: 3570 mg/kg | Behavioral: Coma Lung, Thorax, or Respiration: Respiratory depression Gastrointestinal: Nausea or vomiting | 34ZIAG -,339,1969 |
| oral/human | lowest published toxic dose: 223 mg/kg | Behavioral: Hallucinations, distorted perceptions Cardiac: Pulse rate decreased with fall in BP Vascular: BP lowering not characterized in autonomic section | JLCMAK 12,326,1927 |
| oral/human | lowest published toxic dose: 286 mg/kg | Cardiac: Arrythmias (indlucing changes in conduction) Behavioral: Coma Kidney, Ureter, and Bladder: Other changes | VCVGK* -,97,1984 |
| oral/human | lowest published lethal dose: 571 mL/kg | VCVGK* -,97,1984 | |
| oral/infant | lowest published toxic dose: 13 gm/kg | Behavioral: Somnolence (general depressed activity) Behavioral: Irritability Gastrointestinal: Nausea or vomiting | AJEMEN 10,542,1992 |
| oral/man | lowest published lethal dose: 5272 mg/kg | Behavioral: Coma Vascular: BP lowering not characterized in autonomic section Lung, Thorax, or Respiration: Chronic pulmonary edema or congestion | AJCPAI 38,144,1962 |
| oral/man | lowest published toxic dose: 14432 mg/kg | Behavioral: Coma Vascular: BP lowering not characterized in autonomic section Lung, Thorax, or Respiration: Dyspnea | NEJMAG 277,699,1967 |
| oral/mouse | lethal dose (50 percent kill): 3600 mg/kg | Behavioral: Altered sleep time (including change in righting reflex) Behavioral: Somnolence (general depressed activity) | GISAAA 43(1),8,1978 |
| oral/mouse | lethal dose (50 percent kill): 3600 mg/kg | Behavioral: General anesthetic | VCVGK* -,97,1984 |
| oral/rabbit | lethal dose (50 percent kill): 6410 mg/kg | FAONAU 48A,114,1970 | |
| oral/rat | lethal dose (50 percent kill): 5000 mg/kg | Behavioral: General anesthetic | VCVGK* -,97,1984 |
| oral/rat | lethal dose (50 percent kill): 5045 mg/kg | Behavioral: Altered sleep time (including change in righting reflex) Behavioral: Somnolence (general depressed activity) | GISAAA 43(1),8,1978 |
| parenteral/frog | lowest published lethal dose: 20 gm/kg | Peripheral Nerve and Sensation: Spastic paralysis with/without sensory change Behavioral: Somnolence (general depressed activity) | AIPTAK 50,296,1935 |
| skin/rabbit | lethal dose (50 percent kill): 12800 mg/kg | NPIRI* 1,100,1974 | |
| subcutaneous/mammal (species unspecified) | lowest published lethal dose: 6 gm/kg | Peripheral Nerve and Sensation: Spastic paralysis with/without sensory change Behavioral: General anesthetic Lung, Thorax, or Respiration: Other changes | ATXKA8 16,84,1956 |
| subcutaneous/mouse | lowest published lethal dose: 6 gm/kg | HBTXAC 1,172,1955 | |
| unreported route/human | lowest published lethal dose: 2 mL/kg | JJTOEX 12,341,1999 | |
| unreported route/infant | lowest published toxic dose: 1375 mg/kg | Eye: Other eye effects Behavioral: Somnolence (general depressed activity) Behavioral: Hallucinations, distorted perceptions | PECAE5 9,146,1993 |
| unreported route/man | lowest published lethal dose: 2770 mg/kg | 85DCAI 2,73,1970 |
Other Multiple Dose Data and References
| Route/Organism | Dose | Effect | Reference |
|---|---|---|---|
| inhalation/mouse | lowest published toxic concentration: 10000 ppm/6H/11D- intermittent | Behavioral: General anesthetic Behavioral: Ataxia Related to Chronic Data: Death in the "MULTIPLE DOSE" data type field | NTIS** OTS0522901-2 |
| inhalation/mouse | lowest published toxic concentration: 5000 ppm/6H/13W- intermittent | Behavioral: Somnolence (general depressed activity) Liver: Changes in liver weight Blood: Pigmented or nucleated red blood cells | NTIS** OTS0529356 |
| inhalation/mouse | lowest published toxic concentration: 5000 ppm/6H/13W- intermittent | Behavioral: General anesthetic Behavioral: Ataxia Liver: Changes in liver weight | RTOPDW 23,183,1996 |
| inhalation/mouse | lowest published toxic concentration: 5000 ppm/6H/78W- intermittent | Brain and Coverings: Changes in brain weight Liver: Changes in liver weight Kidney, Ureter, and Bladder: Changes in tubules (including acute renal failure, acute tubular necrosis) | RTOPDW 23,183,1996 |
| inhalation/rat | lowest published toxic concentration: 4900 mg/m3/6H/2W- intermittent | Biochemical: Enzyme inhibition, induction, or change in blood or tissue levels: Multiple enzyme effects | VCVGK* -,97,1994 |
| inhalation/rat | lowest published toxic concentration: 1000 mg/m3/6H/4W- intermittent | Eye: Optic nerve neuropathy | VCVGK* -,97,1994 |
| inhalation/rat | lowest published toxic concentration: 100 mg/m3/4H/17W- intermittent | Kidney, Ureter, and Bladder: Other changes in urine composition Blood: Changes in serum composition (e.g. TP, bilirubin, cholesterol) Biochemical: Enzyme inhibition, induction, or change in blood or tissue levels: True cholinesterase | GTPZAB 29(7),60,1985 |
| inhalation/rat | lowest published toxic concentration: 8000 ppm/8H/20W- intermittent | Peripheral Nerve and Sensation: Sensory change involving peripheral nerve Peripheral Nerve and Sensation: Recording from peripheral motor nerve | ENVRAL 62,148,1993 |
| inhalation/rat | lowest published toxic concentration: 5000 ppm/6H/90D- intermittent | Behavioral: Change in motor activity (specific assay) | TOXID9 14,97,1994 |
| inhalation/rat | lowest published toxic concentration: 2500 ppm/6H/2Y- intermittent | Liver: Changes in liver weight Kidney, Ureter, and Bladder: Other changes in urine composition Kidney, Ureter, and Bladder: Changes in bladder weight | TOXID9 15,183,1995 |
| inhalation/rat | lowest published toxic concentration: 500 mg/m3/4H/122D- intermittent | Liver: Multiple effects Kidney, Ureter, and Bladder: Other changes Nutritional and Gross Metabolic: Weight loss or decreased weight gain | VCVGK* -,98,1994 |
| inhalation/rat | lowest published toxic concentration: 20 mg/m3/24H/90D- continuous | Brain and Coverings: Other degenerative changes Lung, Thorax, or Respiration: Other changes Liver: Multiple effects | VCVGK* -,98,1994 |
| oral/rat | lowest published toxic dose: 2196 mg/kg/122D- intermittent | Endocrine: Effect on menstrual cycle | VCVGK* -,98,1994 |
| oral/rat | lowest published toxic dose: 2196 mg/kg/122D- intermittent | Reproductive: Paternal effects: Spermatogenesis (including genetic material, sperm morphology, motility, and count) | VCVGK* -,98,1994 |
| oral/rat | lowest published toxic dose: 7000 mg/kg/7D- intermittent | Liver: Other changes | TXCYAC 303,133,2013 |
| oral/rat | lowest published toxic dose: 7 mL/kg/7D- intermittent | Liver: Other changes Biochemical: Effect on specific coenzyme: B vitamins including folate | JDGRAX 10(1-2),25,1978 |
| oral/rat | lowest published toxic dose: 11340 mg/kg/45D- intermittent | Endocrine: Effect on menstrual cycle | VCVGK* -,98,1994 |
Reviews
| Organization | Standard | Reference |
|---|---|---|
| American Conference of Governmental Industrial Hygienists (ACGIH) | Threshold Limit Value-time-weighted average 200 ppm;short term exposure limit 400 ppm | DTLVS* TLV/BEI,2013 |
| American Conference of Governmental Industrial Hygienists (ACGIH) | Threshold Limit Value-Not classifiable as a human carcinogen | DTLVS* TLV/BEI,2013 |
| International Agency for Research on Cancer (IARC) | Cancer Review:Animal Inadequate Evidence | IMEMDT 15,223,1977 |
| International Agency for Research on Cancer (IARC) | Cancer Review:Animal Inadequate Evidence | IMEMDT 71,1027,1999 |
| International Agency for Research on Cancer (IARC) | Cancer Review:Human Inadequate Evidence | IMSUDL 7,229,1987 |
| International Agency for Research on Cancer (IARC) | Cancer Review:Human Inadequate Evidence | IMEMDT 71,1027,1999 |
| International Agency for Research on Cancer (IARC) | Cancer Review:Group 3 | IMEMDT 71,1027,1999 |
| TOXICOLOGY REVIEW | JIHTAB 20,428,1938 | |
| TOXICOLOGY REVIEW | CLCHAU 19,361,1973 | |
| TOXICOLOGY REVIEW | FNSCA6 2,67,1973 | |
| TOXICOLOGY REVIEW | TOLED5 140-141,239,2003 | |
| TOXICOLOGY REVIEW | TOLED5 140-141,261,2003 | |
| TOXICOLOGY REVIEW | AJINC* 34,627,2006 | |
| TOXICOLOGY REVIEW | AJEMEN 22,404,2004 | |
| TOXICOLOGY REVIEW | HUTOX* -,577,1996 | |
| TOXICOLOGY REVIEW | HUTOX* -,623,1996 | |
| TOXICOLOGY REVIEW | FCTOD7 47,1287,2009 | |
| TOXICOLOGY REVIEW | NBREV* 5,1,1981 | |
| TOXICOLOGY REVIEW | NTAPM* -,727,1995 | |
| TOXICOLOGY REVIEW | REPTED 32,142,2011 | |
| TOXICOLOGY REVIEW | TOLED5 210,44,2012 | |
| TOXICOLOGY REVIEW | MUREAV 768,27,2016 | |
| TOXICOLOGY REVIEW | RTOPDW 58,395,2010 |
Standards and Regulations
| Organization | Standard | Reference |
|---|---|---|
| Environmental Protection Agency (EPA) Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA) 1988 PESTICIDE SUBJECT TO REGISTRATION OR RE-REGISTRATION | FEREAC 54,7740,1989 | |
| Environmental Protection Agency (EPA) Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA) 1998 STATUS OF PESTICIDES | RED Completed | RBREV* -,290,1998 |
| Mine Safety and Health Administration (MSHA) STANDARD-air | time-weighted average 400 ppm (980 mg/m3) | DTLVS* 3,141,1971 |
| Occupational Exposure Limit IN ARGENTINA, BULGARIA, COLOMBIA, JORDAN check ACGIH TLV; | ||
| Occupational Exposure Limit IN SINGAPORE, VIETNAM check ACGIH TLV | ||
| Occupational Exposure Limit-AUSTRALIA | time-weighted average 400 ppm (983 mg/m3), short term exposure limit 500 ppm (1230 mg/m3), JUL2008 | |
| Occupational Exposure Limit-AUSTRIA | MAK-TMW 200 ppm (500 mg/m3);KZW 800 ppm (2000 mg/m3), 2007 | |
| Occupational Exposure Limit-BELGIUM | time-weighted average 400 ppm (997 mg/m3), MAR2002 | |
| Occupational Exposure Limit-BELGIUM | short term exposure limit 500 ppm (1248 mg/m3), MAR2002 | |
| Occupational Exposure Limit-DENMARK | time-weighted average 200 ppm (490 mg/m3), MAY2011 | |
| Occupational Exposure Limit-FRANCE | VLE 400 ppm (980 mg/m3), FEB2006 | |
| Occupational Exposure Limit-GERMANY | MAK 200 ppm (500 mg/m3), 2011 | |
| Occupational Exposure Limit-HUNGARY | time-weighted average 500 mg/m3, short term exposure limit 2000 mg/m3, Skin, SEP2000 | |
| Occupational Exposure Limit-ICELAND | time-weighted average 200 ppm (490 mg/m3), skin, NOV2011 | |
| Occupational Exposure Limit-JAPAN | ceiling concentration 400 ppm (980 mg/m3), MAY2012 | |
| Occupational Exposure Limit-KOREA | time-weighted average 400 ppm (980 mg/m3), short term exposure limit 500 ppm (1225 mg/m3), 2006 | |
| Occupational Exposure Limit-MEXICO | time-weighted average 400 ppm (980 mg/m3);short term exposure limit 500 ppm (1225 mg/m3), 2004 | |
| Occupational Exposure Limit-NEW ZEALAND | time-weighted average 400 ppm (983 mg/m3); short term exposure limit 500 ppm (1230 mg/m3), JAN2002 | |
| Occupational Exposure Limit-PERU | time-weighted average 200 ppm (491 mg/m3); short term exposure limit 400 ppm (983 mg/m3), JUL2005 | |
| Occupational Exposure Limit-POLAND | MAC(time-weighted average) 900 mg/m3, MAC(short term exposure limit) 1200 mg/m3, JAN1999 | |
| Occupational Exposure Limit-RUSSIA | time-weighted average 10 mg/m3, short term exposure limit 50 mg/m3, JUN2003 | |
| Occupational Exposure Limit-SWEDEN | time-weighted average 150 ppm (350 mg/m3);short term exposure limit 250 ppm (600 mg/m3), JUN2005 | |
| Occupational Exposure Limit-SWITZERLAND | MAK-week 200 ppm (500 mg/m3), KZG-week 400 ppm (1000 mg/m3), JAN2011 | |
| Occupational Exposure Limit-THE NETHERLANDS | MAC-TGG 650 mg/m3, 2003 | |
| Occupational Exposure Limit-THE PHILIPPINES | time-weighted average 400 ppm (980 mg/m3), JAN1993 | |
| Occupational Exposure Limit-TURKEY | time-weighted average 200 ppm (500 mg/m3), JAN1993 | |
| Occupational Exposure Limit-UNITED KINGDOM | time-weighted average 400 ppm (999 mg/m3);short term exposure limit 500 ppm (1250 mg/m3), OCT2007 | |
| Occupational Safety and Health Administration (OSHA) Permissible Exposure Limit (Construction) | 8H time-weighted average 400 ppm (980 mg/m3) | CFRGBR 29,1926.55,1994 |
| Occupational Safety and Health Administration (OSHA) Permissible Exposure Limit (Federal Contractors) | 8H time-weighted average 400 ppm (980 mg/m3) | CFRGBR 41,50-204.50,1994 |
| Occupational Safety and Health Administration (OSHA) Permissible Exposure Limit (General Industry) | 8H time-weighted average 400 ppm (980 mg/m3) | CFRGBR 29,1910.1000,1994 |
| Occupational Safety and Health Administration (OSHA) Permissible Exposure Limit (Shipyards) | 8H time-weighted average 400 ppm (980 mg/m3) | CFRGBR 29,1915.1000,1993 |
NIOSH Documentation and Surveillance
| Organization | Standard | Reference |
|---|---|---|
| National Institute for Occupational Safety and Health (NIOSH) Recommended Exposure Level TO ISOPROPYL ALCOHOL-air | 10H time-weighted average 400 ppm;short term exposure limit 500 ppm | NIOSH* DHHS #92-100,1992 |
| National Occupational Exposure Survey 1983 | Hazard Code 40987; Number of Industries 449; Total Number of Facilities 183402; Number of Occupations 278; Total Number of Employees Exposed 4665524; Total Number of Female Employees Exposed 2058264 | |
| National Occupational Hazard Survey 1974 | Hazard Code 40987; Number of Industries 465; Total Number of Facilities 213605; Number of Occupations 252; Total Number of Employees Exposed 3183554 |
Status in Federal Agencies
Page last reviewed: November 16, 2018
Content
source: National Institute for Occupational Safety and Health